Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRSNASDAQ:EPRXNASDAQ:ESLANASDAQ:FATE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.28-1.2%$1.34$0.95▼$5.17$138.06M0.421.18 million shs61,043 shsEPRXEupraxia Pharmaceuticals$3.76-1.3%$3.59$2.20▼$4.48$134.79MN/A13,934 shs849 shsESLAEstrella Immunopharma$1.01+3.1%$0.96$0.63▼$3.23$36.53M0.4185,497 shs245 shsFATEFate Therapeutics$1.17-0.4%$1.03$0.66▼$5.92$133.40M2.322.23 million shs204,804 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics-4.44%+9.32%+14.16%-44.16%+9.32%EPRXEupraxia Pharmaceuticals-2.31%-3.30%+9.48%+7.32%+32.29%ESLAEstrella Immunopharma+3.06%+2.02%+21.39%-32.21%+2.02%FATEFate Therapeutics-6.40%+21.88%-6.40%-24.27%-68.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRSAclaris Therapeutics2.8661 of 5 stars3.62.00.00.03.51.71.3EPRXEupraxia Pharmaceuticals2.2038 of 5 stars3.83.00.00.00.60.00.6ESLAEstrella Immunopharma1.4964 of 5 stars3.53.00.00.00.01.70.0FATEFate Therapeutics4.3494 of 5 stars4.13.00.04.72.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.13Buy$10.00684.31% UpsideEPRXEupraxia Pharmaceuticals 3.33Buy$10.50179.26% UpsideESLAEstrella Immunopharma 3.00Buy$16.001,484.16% UpsideFATEFate Therapeutics 2.22Hold$4.14255.61% UpsideCurrent Analyst Ratings BreakdownLatest ESLA, ACRS, FATE, and EPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025ACRSAclaris TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $16.005/14/2025FATEFate TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$10.00 ➝ $2.005/14/2025FATEFate TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$5.00 ➝ $4.005/14/2025FATEFate TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/9/2025ACRSAclaris TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$15.00 ➝ $9.003/18/2025ACRSAclaris TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight3/7/2025ACRSAclaris TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$15.003/6/2025FATEFate TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$5.00 ➝ $3.003/6/2025FATEFate TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$5.00 ➝ $4.003/6/2025FATEFate TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$5.00 ➝ $5.003/6/2025FATEFate TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold(Data available from 5/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$17.78M7.77N/AN/A$2.22 per share0.57EPRXEupraxia PharmaceuticalsN/AN/AN/AN/A$0.03 per shareN/AESLAEstrella ImmunopharmaN/AN/AN/AN/A$0.12 per shareN/AFATEFate Therapeutics$13.34M10.01N/AN/A$3.74 per share0.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$88.48M-$1.39N/AN/AN/A-136.65%-40.26%-31.71%8/6/2025 (Estimated)EPRXEupraxia Pharmaceuticals-$28.22M-$0.76N/AN/AN/AN/A-219.64%-96.00%8/6/2025 (Estimated)ESLAEstrella Immunopharma-$7.31M-$0.26N/A∞N/AN/A-195.77%-157.28%N/AFATEFate Therapeutics-$160.93M-$1.49N/AN/AN/A-1,325.43%-45.88%-33.95%N/ALatest ESLA, ACRS, FATE, and EPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025FATEFate Therapeutics-$0.39-$0.32+$0.07-$0.32$1.18 million$1.63 million5/6/2025Q1 2025ACRSAclaris Therapeutics-$0.19-$0.12+$0.07-$0.12$3.55 millionN/A5/6/2025Q1 2025EPRXEupraxia Pharmaceuticals-$0.19-$0.21-$0.02-$0.21N/AN/A3/20/2025Q4 2024EPRXEupraxia Pharmaceuticals-$0.20-$0.21-$0.01-$0.21N/AN/A3/5/2025Q4 2024FATEFate Therapeutics-$0.44-$0.31+$0.13-$0.44$1.57 million$1.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/AEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AESLAEstrella ImmunopharmaN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A7.037.03EPRXEupraxia PharmaceuticalsN/A4.174.17ESLAEstrella ImmunopharmaN/A0.750.75FATEFate TherapeuticsN/A8.298.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%EPRXEupraxia PharmaceuticalsN/AESLAEstrella Immunopharma0.35%FATEFate Therapeutics97.54%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics6.40%EPRXEupraxia PharmaceuticalsN/AESLAEstrella Immunopharma55.10%FATEFate Therapeutics5.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100108.28 million66.86 millionOptionableEPRXEupraxia Pharmaceuticals2935.85 millionN/AN/AESLAEstrella ImmunopharmaN/A36.17 million16.24 millionNot OptionableFATEFate Therapeutics550114.60 million108.20 millionOptionableESLA, ACRS, FATE, and EPRX HeadlinesRecent News About These CompaniesD. E. Shaw & Co. Inc. Decreases Position in Fate Therapeutics, Inc. (NASDAQ:FATE)May 22 at 3:54 AM | marketbeat.comVestal Point Capital LP Increases Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE)May 21 at 8:14 AM | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Holdings Raised by Tang Capital Management LLCMay 20 at 6:24 AM | marketbeat.comSphera Funds Management LTD. Purchases Shares of 397,177 Fate Therapeutics, Inc. (NASDAQ:FATE)May 18, 2025 | marketbeat.comFate Therapeutics (NASDAQ:FATE) Upgraded at StockNews.comMay 18, 2025 | americanbankingnews.comQ2 Earnings Estimate for Fate Therapeutics Issued By WedbushMay 18, 2025 | americanbankingnews.comRobert W. Baird Lowers Fate Therapeutics (NASDAQ:FATE) Price Target to $4.00May 17, 2025 | americanbankingnews.comFate Therapeutics' (FATE) "Hold" Rating Reiterated at Needham & Company LLCMay 17, 2025 | americanbankingnews.comWhat is Leerink Partnrs' Estimate for FATE Q2 Earnings?May 17, 2025 | americanbankingnews.comNeedham Remains a Hold on Fate Therapeutics (FATE)May 16, 2025 | theglobeandmail.comBarclays Reaffirms Their Buy Rating on Fate Therapeutics (FATE)May 16, 2025 | theglobeandmail.comFate Therapeutics (FATE) Receives a Hold from WedbushMay 16, 2025 | theglobeandmail.comFate Therapeutics (NASDAQ:FATE) Receives Hold Rating from Needham & Company LLCMay 16, 2025 | marketbeat.comFate Therapeutics First Quarter 2025 Earnings: Beats ExpectationsMay 15, 2025 | finance.yahoo.comFate Therapeutics, Inc. (NASDAQ:FATE) Shares Purchased by Dimensional Fund Advisors LPMay 15, 2025 | marketbeat.comFate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in FocusMay 14, 2025 | zacks.comIntegral Health Asset Management LLC Lowers Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)May 14, 2025 | marketbeat.comFate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue EstimatesMay 13, 2025 | zacks.comFate Therapeutics Reports First Quarter 2025 Financial Results and Business UpdatesMay 13, 2025 | globenewswire.comFate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy SectorMay 9, 2025 | seekingalpha.comBaker BROS. Advisors LP Grows Position in Fate Therapeutics, Inc. (NASDAQ:FATE)May 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesTesla: Get Ready To See It Trading Above $400 AgainBy Sam Quirke | May 14, 2025View Tesla: Get Ready To See It Trading Above $400 AgainMagnificent 7 Stocks Shift Toward Stability and Selective GrowthBy Gabriel Osorio-Mazilli | May 19, 2025View Magnificent 7 Stocks Shift Toward Stability and Selective GrowthTesla's Band-Aid Has Been Ripped Off: Rally Mode EngagedBy Sam Quirke | April 30, 2025View Tesla's Band-Aid Has Been Ripped Off: Rally Mode EngagedWhy Tesla’s 60% Surge Should Keep Going Into SummerBy Sam Quirke | May 19, 2025View Why Tesla’s 60% Surge Should Keep Going Into SummerTesla Earnings Miss, But Musk Refocuses and Bulls ReactBy Sam Quirke | April 23, 2025View Tesla Earnings Miss, But Musk Refocuses and Bulls ReactESLA, ACRS, FATE, and EPRX Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$1.27 -0.02 (-1.16%) As of 10:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Eupraxia Pharmaceuticals NASDAQ:EPRX$3.76 -0.05 (-1.31%) As of 10:44 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.Estrella Immunopharma NASDAQ:ESLA$1.01 +0.03 (+3.06%) As of 10:13 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.Fate Therapeutics NASDAQ:FATE$1.16 -0.01 (-0.43%) As of 10:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1 Microsoft Could Rally as EU Antitrust Case Nears Resolution Canada Goose Soars 30%—Is This Rally Built to Last? Archer Rebuts Short Seller, Points to Strong Q1 & Global Momentum 5 Reasons You Will Be Glad You Bought Target in 2025 Moderna Stock Looks Ripe for a Short Squeeze Palo Alto Networks: Buy The Dip, Long-Term Tailwinds Ahead Lowe’s Stock Uptrend Can Continue for These 2 Reasons Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
